16th European AIDS Conference (EACS 2017)
The 16th European AIDS Conference (EACS 2017) was held from 25-27 October 2017 in Milan, Italy.
This conference is held every two years (alternating with the Glasgow HIV Congress) and always provides a good focus for European HIV research.
This year the conference abstracts were available online in a searchable database as soon as the meeting started.
Currently, neither slide presentations nor PDF files for posters have been added to the conference website. Also, access to abstracts in only available via the online iPlanner or App, with no direct URLs to individual abstracts.
Early reports from this meeting will be linked to this page.
- Fostemsavir in highly treatment-experienced participants: 24-week phase 3 results
- D/C/F/TAF: phase 3 naive results and splitting PI-based FDC tablets
- Dolutegravir-based dual therapy as switch option in multiple studies
- Switch study shows F/TAF non-inferior to continuing abacavir/3TC
- Twice-daily tenofovir alafenamide dose might overcome interaction with rifampicin
- No impact on bioavailability of D/C/F/TAF when tablet is split but TAF absorption is reduced if crushed
- Studies on dolutegravir and sleep, cardiovascular and CNS side effects, and risk of IRIS
- Dolutegravir use in pregnancy: results from small Belgian cohort
- No transmissions from breastfeeding in Tanzania cohort from mothers with undetectable viral load
- Updated European guidelines launched at EACS 2017
- ABX464 nudges viral reservoir but not time to viral rebound